Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
Hematology/Oncology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA, mohamad-cherry@ouhsc.edu.
Mohamad
M
Cherry
Mohamad
M
Khawandanah
Zhizhuang Joe
ZJ
Zhao
Samer
S
Srour
Howard
H
Ozer
George
G
Selby
Bassam
B
Ghabache
Aref
A
Al-Kali
D000328:Adult; D000368:Aged; D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010649:Phenylalanine / Q000235:genetics; D011087:Polycythemia Vera / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D011799:Quinazolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000235:genetics
D000970:Antineoplastic Agents; D011799:Quinazolines; D010649:Phenylalanine; D000069347:Erlotinib Hydrochloride; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D014633:Valine